Could Clean Earth’s sale transform Enviri into a high-margin industrial services player?
Enviri's potential Clean Earth sale could unlock major value and reshape its portfolio. Find out what investors should watch as the deal progresses. Read More
Investors brush off U.S. government shutdown drama—What this means for Asian stocks
Asian markets show resilience as U.S. shutdown looms, with investors weighing Fed policy, earnings, and data risks over Washington gridlock. Read More
Clean Earth shines as Enviri weighs sale in strategic review; rail weakness clouds Q2 2025 earnings
Enviri launches a strategic review that could involve selling Clean Earth, as Q2 2025 results show rail weakness but record Clean Earth earnings. Read More
Why FMR Resources’ Chile copper JV has investors betting big on a microcap breakout
FMR Resources jumps on Chile copper-gold JV and A$2.2M raise. Find out how its Southern Porphyry drill plan could change the game. Read More
Lupin to launch India’s first green inhalers with Honeywell’s Solstice Air: Can pharma go climate-smart?
Lupin is partnering with Honeywell to launch India’s first low-GWP inhalers using Solstice Air propellant. Find out how it’s reshaping respiratory care. Read More
From crisis to comeback? What the Genesis plan reveals about Atos’ turnaround
Atos launches Genesis plan to regain growth, slash costs, and reach €10B revenue by 2028. See how AI and restructuring are reshaping its turnaround journey. Read More
Why Capgemini’s AI move could make mainframes obsolete faster than anyone expected
Capgemini’s gen AI-powered mainframe modernization aims to transform legacy systems with speed, accuracy, and agility. Find out how the shift is unfolding. Read More
What makes Lowe’s Mylow Companion different from typical retail bots?
Find out how Lowe’s is redefining in-store retail with Mylow Companion, a generative AI assistant built to empower store associates across 1,700+ U.S. stores. Read More
Can Biocon Biologics lead biosimilar disruption in ophthalmology with Yesafili?
Biocon Biologics secures 2026 U.S. launch for Yesafili, its interchangeable biosimilar to Eylea. Find out how this reshapes eye care access and competition. Read More
Why Tahawwur Rana’s custody is testing India’s counterterrorism protocol after his extradition in 26/11 case
Find out how Tahawwur Rana’s extradition is reshaping India’s counterterrorism efforts and what it means for the 26/11 Mumbai attacks investigation. Read More